A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer

Inclusion Criteria: 1. Subjects fully understand and voluntarily participate in this study and sign informed consent; 2. Age ≥18, female; 3. Histologically confirmed diagnosis of epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma (excluding low grade serous carcinoma and mucous carcinoma); 4. Fail to respond to or progressed on the standard platinum-based therapy ; 5. At least one measurable lesion according to RECIST v1.1; 6. ECOG performance status of 0 to 2; 7. Life expectancy ≥ 12 weeks; 8. AEs from the previous treatment have resolved to ≤ Grade 1 based on CTCAE (except for the toxicity without safety risk judged by the investigator, such as hair loss, hyperpigmentation); 9. Adequate organ function; 10. Subjects of childbearing potential must agree to use effective contraceptive measures. Female subjects must have a negative pregnancy test before enrolment; 11. Fully comply with the protocol. Exclusion Criteria: 1. History of allergy to mitoxantrone hydrochloride or any excipients of the study drug; 2. Untreated or symptomatic central nervous system (CNS) metastases; 3. Pericardial effusion with clinical symptoms 4. History of allotransplantation; 5. Known hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) or other active viral infection; 6. Serious infection or interstitial pneumonia within 1 week prior to the first dose administration; 7. Use of other anticancer treatment within 4 weeks prior to the first dose administration; 8. Enrolled in any other clinical trials within 4 weeks prior to the first dose administration; 9. Major surgery within 3 months prior to the first dose administration, or have a surgical schedule during the study period; 10. Thrombosis or thromboembolism within 6 months prior to screening; 11. History of, or known additional malignant tumor within 3 years, except for tumors have been cured and have not recurred, and carcinoma in situ; 12. Impaired cardiac function or serious cardiac disease; 13. Previous treatment with adriamycin or other anthracyclines, and the total cumulative dose of prior adriamycin or equivalent is \>350 mg/m2. 14. Pregnant or lactating female; 15. Serious and/or uncontrolled systemic diseases; 16. Not suitable for this study as decided by the investigator due to other reasons.